Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend
The rapid adoption of GLP-1 weight loss medications — drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro — is reshaping how Americans eat and shop. It’s also changing how major corporations do business. From new product lines to expanding certain categories, companies are trying to capitalize on the lifestyle shifts […]
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly’s ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec….
Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS
Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for PCOS rose over sevenfold in the US since 2021. #pcos #glp1 #novonordisk #elililly #hormonaldisorder #News #Reuters #Newsfeed Read the story here: https://reut.rs/4rGTKhD 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest […]
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations. The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.
Looming GLP-1 drug patent expirations draw generics firms
India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year
GLP-1s may not affect obesity-related cancer risk: Study
A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers. The study, published Dec. 9 in Annals of Internal Medicine, is based on a review of 48 randomized controlled trials involving 94,245 […]
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott Reule Sean Pickthorn Stefanie Worwa Areef Ishani Robert Foley Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists […]
Pfizer inks $2B deal for early-stage GLP-1
Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist currently in phase 1 development for chronic weight management. YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, will complete the ongoing phase 1 clinical trial and grant Pfizer exclusive worldwide […]
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden says
ORLANDO, Fla. — Eli Lilly’s new chief dealmaker is planning to spend its GLP-1 cash in an “aggressive” but responsible manner. Last month, Lilly’s president of oncology Jacob Van Naarden was